Cetuximab單抗生物相似藥市場規模、佔有率和成長分析：按適應症/治療應用、劑型、治療策略、最終用戶和地區分類 - 行業預測，2026-2033年

2024 年全球Cetuximab單抗生物相似藥市值為 1.254 億美元，預計到 2033 年將從 2025 年的 1.4923 億美元成長至 6.01 億美元，在預測期（2026-2033 年）內複合年成長率為 19.0%。

Cetuximab單抗生物相似藥市場的主要促進因素是原廠藥專利到期以及支付方降低癌症治療成本的壓力日益增大，這為生物類似藥的研發提供了強大的經濟獎勵。由於Cetuximab單抗在生物製藥癌症治療成本中佔據相當大的比例，生物相似藥開發商旨在透過提供價格更低的替代藥物來吸引注重預算的消費者，從而改善患者的用藥可及性，並幫助醫院在更緊張的預算下運作。受採購政策和生產效率影響的價格趨勢對市場成長至關重要，因為較低的價格會鼓勵患者儘早開始治療，從而提高治療率。此外，人工智慧正在革新定價策略，它將細粒度的臨床和支付方數據轉化為可執行的洞察，最佳化競標提案，並實現個人化方法以利用區域市場趨勢，最終推動市場擴張。

全球Cetuximab單抗生物相似藥市場促進因素

全球Cetuximab生物相似藥市場的發展得益於監管流程的改進，這些改進最大限度地減少了研發者的不確定性，並明確了產品等效性的預期。這項改進將鼓勵加大投資，並加速生物相似藥研發管線的進展。統一的指南和清晰的核准框架，透過明確具體的臨床和分析要求，獎勵製造商積極參與研發，從而縮短研發週期並降低監管風險。此外，這些流程的完善確保了品質和安全評估的一致性，增強了包括臨床醫生和支付方在內的相關人員的信心。這有助於西Cetuximab生物相似藥從研發階段成功過渡到市場，並最終獲得更廣泛的認可。

全球Cetuximab單抗生物相似藥市場面臨的限制因素

全球Cetuximab單抗生物相似藥市場面臨諸多限制因素，主要源自於專利和訴訟方面的挑戰，這些挑戰阻礙了市場准入並延緩了商業化進程。圍繞智慧財產權的法律不確定性和曠日持久的糾紛耗盡了生物相似藥研發公司的資源，迫使它們將精力集中在法律辯護而非研發上。這種情況減緩了新產品的上市速度，並抑制了市場競爭。此外，曠日持久的法律訴訟也可能嚇退投資者和商業夥伴，導致參與企業數量減少，並限制了擴大患者獲得西Cetuximab單抗生物類似藥的機會。

全球Cetuximab單抗生物相似藥市場趨勢

全球Cetuximab單抗生物相似藥市場正經歷顯著成長，這主要得益於保險公司和醫療服務提供者接受度的不斷提高。這種轉變促使更多患者將生物相似藥納入健保覆蓋範圍，簡化採購流程，並擴大了這些藥物的可近性。生產商正致力於打造有效的價值提案、開展患者支持項目，並開展醫護人員宣傳活動，這些對於將生物類似藥整合到標準治療通訊協定中至關重要。此外，優先考慮成本效益高的療法的政策趨勢正在加速生物相似藥的普及，而與經銷商和當地企業的策略合作正在加強分銷網路，尤其是在服務不足的市場，從而改善了供應，並確保了有需要的患者能夠獲得公平的治療。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球Cetuximab單抗生物相似藥市場規模：依適應症/治療應用分類

• 轉移性大腸直腸癌（mCRC）
• 頭頸部鱗狀細胞癌（HNSCC）

全球Cetuximab單抗生物相似藥市場規模：按劑型分類

• 靜脈輸液

全球Cetuximab單抗生物相似藥市場規模：依治療策略分類

• 主要治療
• 二線治療/聯合治療

全球Cetuximab單抗生物相似藥市場規模：依最終用戶分類

• 癌症專科醫院
• 門診化療中心
• 學術研究機構

全球Cetuximab單抗生物相似藥市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要企業2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要企業的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要企業簡介

• Amgen Inc.
• Merck & Co., Inc.
• Pfizer Inc.
• Samsung Bioepis
• Mylan NV
• Teva Pharmaceutical Industries Ltd.
• Celltrion Healthcare Co., Ltd.
• Sandoz International GmbH
• Gensight Biologics
• AbbVie Inc.
• Biosimilars Inc.
• Biocon Limited
• UCB Pharma
• Cipla Limited
• Fresenius Kabi AG
• Wockhardt Ltd.
• Zydus Cadila
• Intas Pharmaceuticals
• Coherus BioSciences, Inc.
• Novartis AG

結論與建議

Global Cetuximab Biosimilar Market size was valued at USD 125.4 Million in 2024 and is poised to grow from USD 149.23 Million in 2025 to USD 600.1 Million by 2033, growing at a CAGR of 19.0% during the forecast period (2026-2033).

The cetuximab biosimilar market is primarily driven by the expiration of originator patents and increased payer pressure to reduce oncology costs, creating strong economic incentives for biosimilar development. As cetuximab is a significant contributor to biological oncology spending, biosimilar developers aim to attract budget-conscious consumers by providing lower-cost alternatives, thereby enhancing patient access and enabling hospitals to operate within tighter budgets. Pricing dynamics influenced by procurement policies and manufacturing efficiencies are essential for growth, as lower prices encourage early initiation of therapy and increase patient treatment volumes. Additionally, AI is revolutionizing pricing strategies by transforming segmented clinical and payer data into actionable insights, optimizing tender proposals, and allowing for tailored approaches to capitalize on local market dynamics, ultimately driving market expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cetuximab Biosimilar market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cetuximab Biosimilar Market Segments Analysis

Global cetuximab biosimilar market is segmented by indication/therapeutic use, dosage form, line of treatment, end-user and region. Based on indication/therapeutic use, the market is segmented into Metastatic Colorectal Cancer (mCRC) and Head and Neck Squamous Cell Carcinoma (HNSCC). Based on dosage form, the market is segmented into Intravenous (IV) Infusion. Based on line of treatment, the market is segmented into First-line Therapy and Second-line/Combination Therapy. Based on end-user, the market is segmented into Oncology Specialty Hospitals, Outpatient Chemotherapy Centers and Academic Research Institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Cetuximab Biosimilar Market

The global Cetuximab biosimilar market is driven by enhanced regulatory pathways that minimize uncertainty for developers, providing clearer expectations regarding product comparability. This improvement fosters increased investment and accelerates advancements in biosimilar pipelines. Harmonized guidelines and clear approval frameworks incentivize manufacturers to engage in development by outlining specific clinical and analytical requirements, which can lead to shortened timelines and reduced regulatory risks. Additionally, these defined pathways enhance confidence among stakeholders, including clinicians and payers, by ensuring consistent quality and safety assessments. This, in turn, facilitates the transition from development efforts to successful market introductions and wider acceptance of Cetuximab biosimilars.

Restraints in the Global Cetuximab Biosimilar Market

The global cetuximab biosimilar market faces significant restraints primarily due to patent and litigation challenges that hinder market entry and delay the commercialization process. Legal uncertainties and prolonged disputes surrounding intellectual property rights can divert considerable resources from biosimilar sponsors, forcing them to focus on legal defense instead of development. This situation slows down new product introductions and stifles market competition. Additionally, the potential for lengthy legal battles deters investors and commercial partners, thereby reducing the number of market entrants and constraining the overall capacity to enhance patient access to cetuximab biosimilars.

Market Trends of the Global Cetuximab Biosimilar Market

The global cetuximab biosimilar market is experiencing a significant upward trend driven by increasing acceptance among payers and healthcare institutions. This shift is enhancing formulary inclusion and streamlining procurement processes, enabling broader accessibility to these biosimilars. Manufacturers are focusing on effective value messaging, patient support initiatives, and educational outreach for healthcare professionals, which are crucial for their integration into standard care protocols. Additionally, policy trends prioritizing cost-effective therapeutics are fostering uptake, while strategic partnerships with distributors and local entities are enhancing distribution networks, especially in underserved markets, thereby improving availability and equity in care for patients who need it.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Cetuximab Biosimilar Market Size by Indication/Therapeutic Use & CAGR (2026-2033)

• Market Overview
• Metastatic Colorectal Cancer (mCRC)
• Head and Neck Squamous Cell Carcinoma (HNSCC)

Global Cetuximab Biosimilar Market Size by Dosage Form & CAGR (2026-2033)

• Market Overview
• Intravenous (IV) Infusion

Global Cetuximab Biosimilar Market Size by Line of Treatment & CAGR (2026-2033)

• Market Overview
• First-line Therapy
• Second-line/Combination Therapy

Global Cetuximab Biosimilar Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Oncology Specialty Hospitals
• Outpatient Chemotherapy Centers
• Academic Research Institutes

Global Cetuximab Biosimilar Market Size & CAGR (2026-2033)

• North America (Indication/Therapeutic Use, Dosage Form, Line of Treatment, End-User)
  • US
  • Canada
• Europe (Indication/Therapeutic Use, Dosage Form, Line of Treatment, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Indication/Therapeutic Use, Dosage Form, Line of Treatment, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Indication/Therapeutic Use, Dosage Form, Line of Treatment, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Indication/Therapeutic Use, Dosage Form, Line of Treatment, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Bioepis
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celltrion Healthcare Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gensight Biologics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biosimilars Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UCB Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Kabi AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Wockhardt Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Cadila
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intas Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Coherus BioSciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations